Marken Opens New Location in Brisbane, Australia
News Oct 27, 2016
Marken has announced the opening of its 44th location in Brisbane to strengthen its Australian operations. The opening of the new office is a result of rapid growth in the region and will support Marken’s existing office in Sydney. The newest location allows an expanded service opportunity for Marken’s clients which include pharma, biotech, Contract Manufacturing Organizations (CMOs) and Clinical Research Organizations (CROs) which operate multiple central laboratories in the region.
Other Marken clients include local medical facilities and hospitals, along with private laboratories which depend on Marken to provide 24/7/365 service to collect and safely transport their time and temperature-sensitive biological samples and urgent pharmaceutical products to destinations around the globe.
Marken’s team of experts in Brisbane will strengthen the growing relationship with existing clients and investigator sites as well as offer additional flexibility to the Marken network for collecting and transporting biological samples, drug product and other clinical trial materials. The new branch office is also located close to the Brisbane airport which will increase efficiency for clients who can take advantage of direct same-day flight options which can provide rapid delivery to Singapore and other major cities across the US and Europe.
Drug products as well as other time and temperature sensitive shipments are tracked in real time using the Marken SentryTM device which monitors exact location, temperature and package condition, including light (open box). All shipments are tracked around the clock from Marken’s Global Control Center in Mumbai.
Bronwen Medley, Regional Director for Marken Australia and New Zealand commented: “Following the success of our operation in Sydney, we are pleased to open a second branch in Brisbane to better serve the local area. A significant number of our Australian customers are based in Brisbane and it’s important to offer these clients Marken’s personalized service on the ground as well as flexibility to evolve our services as needed to accommodate our client’s needs.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019